ANNUAL REPORT AND ACCOUNTS 2014 Financial Review The financial results of the year reflect the Groups sustainable model of deploying patient capital into our continuously growing portfolio of Group controlled businesses at the right pace.
We significantly strengthened our balance sheet with the proceeds from the Companys listing on the London Stock Exchange in 2014 which raised $155.
0 million before issue costs as well as $54.
5 million raised from external investors directly into our subsidiaries.
Consolidated Statement of Comprehensive Loss For the years ended 31 December 2014 2013 $000 $000 Revenue 7,715 2,936 Cost of revenue 5,416 2,342 Selling, general and administrative expenses 38,032 27,472 Research and development expenses 22,195 15,689 Finance income cost 222 140 Other comprehensive loss income 159 35 Total comprehensive loss of which attributable to: 57,865 42,672 Equity holders of the parent 45,637 34,466 Non-controlling interests 12,228 8,206 Revenue increased by $4.
This increase is mainly attributable to the higher product revenue at RF Biocidics, as well as the increasing sales at CryoXtract systems when compared to last year.
The revenue in the early stage companies segment remained relatively consistent at $0.
Cost of revenue increased by $3.
1 million, proportionately to the increase in revenue from prior year.
Selling, general and administrative SG&A expenses increased by $10.
0 million for the year ended 31 December 2014 2013: $27.
5 million largely due to incremental cost incurred due to the IPO in June 2014 as well as the overall growth of the Group.
9 million relates to an increase in personnel expenses reflecting the increase in headcount and salaries as well as the increase in non-cash share-based compensation expense by $2.
4 million was due to the acceleration of vesting of options under the old US Stock Plan upon the IPO in addition to instituting the new UK LTIP plan under Allied Minds plc.
The increase is also attributed to some incremental cost incurred in 2014 associated with the listing of Allied Minds on the London Stock Exchange, which is not otherwise offset against the net proceeds from the offering, reflected mainly in a $3.
0 million increase in professional services to $5.
Research and development R&D expenses increased by $6.
2 million for the year ended 31 December 2014 2013: $15.
The increase is attributed to the overall growth of the Groups research and development activities, reflecting the creation of six new subsidiaries in 2014 and ramping up full scale of R&D activities of companies created in late 2012 and into 2013.
As a result of the above discussed factors, total comprehensive loss increased by $15.
9 million for the year ended 31 December 2014 2013: $42.
Total comprehensive loss for the Page 34 of 152 c111026.
indb 34 25 04 2015 02:07 Strategic Report ANNUAL REPORT AND ACCOUNTS 2014 Financial Review continued year attributed to the equity holders of the Group was $45.
2 million was attributable to the owners of non-controlling interests.
Consolidated Statement of Financial Position As of 31 December 2014 2013 $000 $000 Non-current assets 44,039 23,027 Current assets 248,991 108,778 Total assets 293,030 131,805 Non-current liabilities 717 3,210 Current liabilities 12,499 8,736 Equity 279,814 119,859 Total liabilities and equity 293,030 131,805 Significant  events and business developments reflected in the Companys financial position at year end include: Property and equipment decreased by $1.
0 million, mainly reflecting depreciation expense of $2.
3 million for the period, the sale of machines in normal trade for $2.
8 million and reclass of remaining systems into inventory for $1.
3 million at RF Biocidics, offset by capital purchases for the period of approximately $4.
9 million by Spin Transfer: Intangible assets as of 31 December 2014 decreased by $1.
5 million mainly as a result of amortisation expense of $0.
1 million of intellectual property returned by SciFluor, offset by new additions of $0.
4 million in software and licences purchases and $0.
2 million in capitalised development costs in CryoXtract: Investment in associate increased to $1.
6 million 2013: nil as a result of the investment by one of the subsidiaries.
In March 2014, RF Biocidics acquired a minority interest of 28.
5% in Stalam SpA Stalam in Italy, a manufacturer of radio frequency equipment for $1.
5 million: Other investments, non-current increased to $22.
2 million 2013: nil reflecting the investment of excess cash into fixed income government and corporate securities that have maturities longer than twelve months: Other non-current assets, including non-current financial assets remained relatively consistent at $0.
5 million when compared to prior year: Cash and cash equivalents increased by $119.
The increase is mainly attributed to the net proceeds from the IPO of approximately $142.
5 million from the exercise of options in Allied Minds, plus approximately $54.
5 million from the third-party investors in subsidiary rounds in 2014, of which $50 million was invested in Spin Transfer.
The increase in cash and equivalents for the year was offset by $45.
4 million net cash used in operations, $40.
7 million used in capital and other investing activities, Page 35 of 152 c111026.
indb 35 25 04 2015 02:07 ANNUAL REPORT AND ACCOUNTS 2014 Financial Review continued of which $37.
4 million for the purchase of fixed income security investments, and $3.
3 million used in financing activities for repayment of loans: Other investments, current increased to $15.
2 million 2013: nil reflecting the investment of excess cash into fixed income government and corporate securities that have maturities shorter than twelve months: Inventories increased by $1.
0 million reflecting the purchases of inventories of $2.
2 million and the reclass of $1.
3 million from property and equipment mentioned above, offset by cost of goods sold of $2.
5 million: Trade and other receivables increased by $3.
9 million as a result of increase in prepaid and other current assets of $4.
2 million, net of their amortisation, mainly from advance payments for inventory units at RF Biocidics of $3.
0 million, offset by trade receivables net decrease of $0.
8 million reflecting collections of receivables from sales that were invoiced close to 31 December 2013 at RF Biocidics and CryoXtract: The loans balance, current and non-current, decreased to $0.
8 million reflecting the repayment of the loans at CryoXtract and Spin Transfer.
The loan at Spin Transfer was fully repaid in 2014: With the increase of its sales and pipeline, RF Biocidics is collecting deposits from customers as installment payments against purchases of its products.
This accounts for the majority of the deferred revenue balance current and non-current of $1.
1 million as of 31 December 2014, which decreased from $2.
8 million as of 31 December 2013 as revenue from these sales was recognised in 2014: and As noted above, Allied Minds completed an IPO and listed on the Main Market of the LSE in June 2014, which is the main factor for the increase in the share premium to $153 million as of 31 December 2014 2013: nil.
Additionally, other reserve increased by approximately $9.
8 million as a result of the share-based compensation expense charge for the period.
Due to the merger of Allied Minds, Inc. now Allied Minds LLC into Allied Minds plc as part of the IPO process in June 2014 all issued and outstanding options under the US Stock Plan vested on 19 June 2014 and 7,662,424 options were exercised, resulting in the accelerated share-based payment charge of additional $2.
5 million from the third-party investors in subsidiary rounds were contributed to non-controlling interests in 2014.
The additions to total equity were offset by the net comprehensive loss for the year of $57.
indb 36 25 04 2015 02:07 Strategic Report ANNUAL REPORT AND ACCOUNTS 2014 Financial Review continued Consolidated Statement of Cash Flows For the years ended 31 December 2014 2013 $000 $000 Net cash outflow from operating activities 45,377 35,078 Net cash outflow from investing activities 40,731 10,675 Net cash inflow from financing activities 205,632 116,555 Net increase in cash and cash equivalents 119,524 70,802 Cash and cash equivalents in the beginning of the year 104,551 33,749 Cash and cash equivalents at the end of the year 224,075 104,551 The Groups net cash outflow from operating activities of $45.
1 million was primarily due to the net operating losses for the year of $57.
9 million plus the net effect from movement in working capital and other net finance cost of $1.
0 million, offset by adjustment for non-cash items such as depreciation, amortisation, and share-based expenses of $13.
3 million and interest received net of paid of $0.
The Group had a net cash outflow from investing activities of $40.
7 million mainly reflecting the purchases of fixed income investment securities of $37.
4 million and the acquisition of minority interest in associate by RF Biocidics of $1.
These outflows were offset by $9.
3 million lower purchases of property and equipment, when compared to higher capital purchases in 2013 due to the build out of a clean room for the research and development activities at Spin Transfer Technologies, as well as capital purchases of equipment at some of the other subsidiaries.
The Groups net cash inflow from financing activities of $205.
6 million largely reflects the net proceeds from the IPO of approximately $142.
5 million proceeds from the exercise of stock options under the US Stock Plan, compared to net proceeds from the Series B round in Allied Minds, Inc. now Allied Minds, LLC in 2013.
Additionally, this increase reflected higher proceeds from issuance of share capital in subsidiaries of $54.
5 million from the rounds in AlliedBristol Life Sciences, Optio Labs and Spin Transfer in 2014, compared to the second tranche of $14.
5 million from STTs financing round received in 2013.
The cash provided in financing activities was offset by the net repayments of loans at CryoXtract and STT of $3.
2 million compared to net borrowings against the loans of $2.
The Groups strategy is to maintain healthy, highly liquid cash balances that are readily available to support the activities of its subsidiaries by providing working capital, maintaining the level of research and development activities required to achieve the set milestone goals, and acquiring capital equipment where necessary to support research and development activities.
To further minimise its exposure to risks the Group does not maintain any material borrowings or cash balances in foreign currency.
